CYIOS Corporation (OTC: CYIO) Announces Leadership Transition and Engages Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors

Rhea-AI Summary

CYIOS Corporation (OTC: CYIO) announced a leadership transition and strategic steps to strengthen its balance sheet. David Lewis has stepped down and voluntarily returned 16,560 Series D preferred shares and cancelled outstanding salary and loan obligations, simplifying the capital structure. The company said it has completed 2024 PCAOB-audited financial statements and is working with its auditor to finish two years of PCAOB-audited statements to improve transparency.

CYIOS targets increasing working capital and paying down Noir Medical Supplies’ debt by mid-2026, and plans to engage AI and SaaS advisors to scope and cost the CyioIQ AI-driven medical platform to boost efficiency and third-party distribution opportunities.

Positive

• 16,560 Series D preferred shares returned to company
• 2024 PCAOB-audited financial statements completed
• Target to pay Noir Medical debt by mid-2026
• Engaging AI/SaaS advisors to scope CyioIQ platform

Negative

• Noir Medical debt remains until target mid-2026 payoff
• CyioIQ advisor engagement is planning-stage with no guaranteed outcomes

MELBOURNE, Australia and PALM BEACH, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CYIOS Corporation (OTC: CYIO) today announced that David Lewis has stepped down from his roles with CYIOS, and as part of this transition, he has voluntarily agreed to return 16,560 Series D Preferred Shares to the Company, and cancel all outstanding salary and loan obligations. This decisive step strengthens the company’s balance sheet, simplifies its capital structure, and positions CYIOS for its next stage of growth. We wish David all the best for his next endeavor.

CYIOS is also working closely with its independent auditor to complete two years of PCAOB-audited financial statements, with 2024 being fully completed, which is an important milestone toward enhancing transparency and compliance. In parallel, the company continues to focus on increasing working capital through strategic investment initiatives aimed at paying down Noir Medical Supplies’ debt obligations, a key priority expected to be completed by mid-2026.

“These are meaningful milestones in strengthening CYIOS’ foundation for growth,” said Mr. John O’Shea, Chairman and CEO of CYIOS Corporation. “We remain committed to disciplined financial management, profitable expansion, and delivering long-term value to our shareholders.”

Mr. O’Shea is also excited to announce that CYIOS is now looking to engage Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors to help map out CyioIQ: CYIO’s AI-Driven Medical Platform scope, architecture, design, business case, and build cost for a comprehensive AI-driven platform. This initiative aims to maximize CYIOS’s position within the medical and health supply industry. The implementation of AI is expected to streamline operations within Noir Medical Supplies, driving greater efficiency, strengthening bottom-line profitability, and unlocking potential new revenue streams through third-party distribution partnerships with other industry players. More information on this exciting development will follow.

CYIOS Corporation
CYIOS Corporation (OTC: CYIO) is a diversified holding company focused on building, acquiring, and operating innovative businesses across multiple industries, including medical supplies, technology, and fintech. Through its subsidiary Noir Medical Supplies, CYIOS continues to expand its presence in the U.S. medical distribution sector, emphasizing operational excellence and sustainable profitability.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that involve risks and uncertainties that could cause actual results to differ materially. CYIOS undertakes no obligation to update or revise any forward-looking statements except as required by law.

Contact:
Investor Relations
CYIOS Corporation
info@cyioscorporation.com
www.cyioscorporation.com

FAQ

What did CYIOS (OTC: CYIO) announce on October 21, 2025 about leadership?

CYIOS said David Lewis stepped down and voluntarily returned 16,560 Series D preferred shares while cancelling salary and loan obligations.

Has CYIOS completed audited financials for 2024 (OTC: CYIO)?

The company reported 2024 PCAOB-audited financial statements are fully completed and it is working to finish two years of PCAOB-audited statements.

When does CYIOS plan to pay down Noir Medical Supplies’ debt (CYIO)?

CYIOS expects the repayment of Noir Medical Supplies’ debt to be completed by mid-2026.

What is CyioIQ and what will CYIOS (CYIO) do next?

CyioIQ is described as an AI-driven medical platform; CYIOS plans to engage AI and SaaS advisors to map scope, design, business case, and build cost.

How will the AI initiative affect Noir Medical Supplies and CYIO shareholders?

The company says AI implementation aims to streamline Noir Medical operations, improve profitability, and enable potential new third-party distribution revenue streams.